Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

References

• Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175–191.
   PubMedGoogle Scholar
• Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int J Antimicrob Agents. 2008;32(Suppl 2):S119–23.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, Mihu CN, et al. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant. 2010;45(2):339–347.
   Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–273.
   PubMed Web of Science ®Google Scholar
• Phikulsod P, Suwannawiboon B, Chayakulkeeree M. Invasive fungal infection among febrile patients with chemotherapy-induced neutropenia in Thailand. Southeast Asian J Trop Med Public Health. 2017;48(1):159–169.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–851.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Dekkers BGJ, Bakker M, van der Elst KCM, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51–61.
   PubMed Web of Science ®Google Scholar
• Petitcollin A, Boglione-Kerrien C, Tron C, et al. Population pharmacokinetics of posaconazole tablets and monte carlo simulations to determine whether all patients should receive the same dose. Antimicrob Agents Chemother. 2017;61(11):e01166–e01217.
   Web of Science ®Google Scholar
• Chen L, Krekels EHJ, Verweij PE, et al. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671–695.
   PubMed Web of Science ®Google Scholar
• Boonsathorn S, Cheng I, Kloprogge F, et al. Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children. Clin Pharmacokinet. 2019;58(1):53–61.
   PubMed Web of Science ®Google Scholar
• Vicenzi EB, Calore E, Decembrino N, et al. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. Eur J Haematol. 2018;100(3):315–322.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205–3216.
   PubMed Web of Science ®Google Scholar
• U.S. Deprment of Health and Human Services NioH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0; 2017 [ cited January 4, 2021]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed July 20, 2021.
   Google Scholar
• Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–1376.
   PubMed Web of Science ®Google Scholar
• Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses Study Group and European organization for research and treatment of cancer consensus criteria. Clin Infect Dis. 2008;47(5):674–683.
   PubMed Web of Science ®Google Scholar
• Döring M, Eikemeier M, Cabanillas SKM, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis. 2015;34(6):1189–1200.
   Web of Science ®Google Scholar
• Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61(3):393–400.
   PubMed Web of Science ®Google Scholar
• FDA. U.S. Noxafl instruction 2015. U.S.: FDA; [ cited January 4, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205053s1lbl.pdf. Accessed July 20, 2021.
   Google Scholar
• Döring M, Cabanillas SKM, Klinker H, et al. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Med Mycol. 2017;55(4):375–384.
   Web of Science ®Google Scholar
• Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2014;33(4):629–638.
   PubMed Web of Science ®Google Scholar
• Döring M, Müller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012;12:263.
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Colita A, Bica AM, et al. Pharmacokinetics of posaconazole oral suspension in children dosed according to body surface area. Pediatr Infect Dis J. 2016;35(2):183–188.
   PubMed Web of Science ®Google Scholar
• McMahon J, Théorêt Y, Autmizguine J, et al. Posaconazole plasma monitoring in immunocompromised children. J Pediatric Infect Dis Soc. 2017;6(4):389–392.
   Web of Science ®Google Scholar
• Heinz WJ, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Med Mycol. 2016;54(2):128–137.
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Herbrüggen H, Ahlmann M, et al. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. J Antimicrob Chemother. 2019;74(12):3573–3578.
   PubMed Web of Science ®Google Scholar